Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etrumadenant + mFOLFOX in Advanced GI Malignancies
NCT03720678Phase 1Completed
- Sponsor
- Arcus Biosciences
- Start
- Nov 2018
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of etrumadenant in gastroesophageal junction cancer and colorectal cancer (CRC) (3 arms), sponsored by Arcus Biosciences. Primary endpoints: Incidence of Adverse Events and Incidence of Dose-Limiting Toxicities at 28 days. Started Nov 2018; status: completed.
02
Drugs
etrumadenant
03
Conditions
gastroesophageal junction cancercolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03720678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03720678.